Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bradley J. Monk, Ignacio Romero, David M. O'Malley, Corina Martinez Mena, Lyndsay Willmott, Annika Auranen, Brian M. Slomovitz, Alice Bergamini, Emily N. Prendergast, Thibault de La Motte Rouge, Colleen C. McCormick, Elena Ioana Braicu, Floor Jenniskens Backes, Jose Alejandro Perez-Fidalgo, Richard G. Moore, Giorgio Valabrega, Roisin Eilish O'Cearbhaill, Sunkyung Kim, Manjinder Bains, Antonio González-Martín
Institutions: Gynecologic Oncology Group, Florida Cancer Specialists & Research Institute, Fundación Instituto Valenciano de Oncología, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Centre Hospitalier Universitaire de Saint-Pierre, Tampere University, Tampere University Hospital, Florida International University, Mount Sinai Medical Center, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Minnesota Oncology, Centre Eugène Marquis, Legacy Health, Charité - Universitätsmedizin Berlin, Universitat de València, INCLIVA Health Research Institute, University of Rochester Medicine, University of Rochester, A. O. Ordine Mauriziano di Torino, University of Turin, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, GlaxoSmithKline (United States), GlaxoSmithKline Research & Development Limited (United Kingdom), Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162519366
Cites:
Cited by:
Related to: